NEW YORK (GenomeWeb News) – Sequenom said today that it has obtained exclusive rights to Genomic Nanosystems’ digital PCR technologies and techniques.
The agreement gives Sequenom exclusive rights to use the digital PCR methods for non-invasive, prenatal diagnostic testing and sample analysis on any platform. In addition, the company will have exclusive rights to use digital PCR in conjunction with mass spectrometry for all commercial, diagnostic, or research applications except second-generation sequencing.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.